IFRX

InflaRx Reports First Quarter 2021 Financial & Operating Results

InflaRx's Vilobelimab Hits Primary Endpoint Goal In Late-Stage ANCA-Associated Vasculitis Study

InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study

InflaRx Reports Full Year 2020 Financial & Operating Results

InflaRx to Present at Upcoming Investor Conferences

InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants

InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants